Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Cancer Research

• Publication date

  1988-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 3191501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation.

  1988cited by this paper
• Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

  1987cited by this paper
• Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

  1987cited by this paper
• Determination of hexamethylene bisacetamide by capillary gas chromatography.

  1987cited by this paper
• Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs.

  1987cited by this paper
• Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.

  1987cited by this paper
• Induction of transformed cells to terminal differentiation and the modulation of gene expression.

  1987cited by this paper
• Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.

  1986cited by this paper
• Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.

  1986cited by this paper
• Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.

  1986cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Erythroleukemic differentiation.

  1978cited by this paper
• Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells.

  1977cited by this paper
• Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide.

  1971cited by this paper

• HMBA ameliorates obesity by MYH9‐ and ACTG1‐dependent regulation of hypothalamic neuropeptides

  2023cites this paper
• Overexpression Bombyx mori HEXIM1 Facilitates Immune Escape of Bombyx mori Nucleopolyhedrovirus by Suppressing BmRelish-Driven Immune Responses

  2022cites this paper
• Dimethyl sulfoxide (DMSO) enhances direct cardiac reprogramming by inhibiting the bromodomain of coactivators CBP/p300.

  2021cites this paper
• Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer

  2020cites this paper
• BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

  2020cites this paper
• Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells

  2019cites this paper
• HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen.

  2017cites this paper
• Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.

  2016cites this paper
• Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanism.

  2016cites this paper
• Lead optimization of HMBA to develop potent HEXIM1 inducers.

  2014cites this paper
• HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents

  2013cites this paper
• Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis

  2012cites this paper
• Determination of hexamethylene bisacetamide, an antineoplastic compound, in mouse and human plasma by LC-MS/MS.

  2011cites this paper
• HIV reservoirs, latency, and reactivation: prospects for eradication.

  2010cites this paper
• HMBA depolymerizes microtubules, activates mitotic checkpoints and induces mitotic block in MCF-7 cells by binding at the colchicine site in tubulin.

  2010cites this paper
• Effective double-ended chelating agents: crystal structures of N,N,N′,N′-tetraacetyl diamino derivatives and their chelates

  2010cites this paper
• The Challenge of Finding a Cure for HIV Infection

  2009cites this paper
• Growth and differentiation factors as cancer therapeutics

  2009cites this paper
• Differentiation Therapy of Cancer : Journey from the Laboratory into the Clinic

  2009influential citation
• Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL).

  2008cites this paper
• Hexamethylene bisacetamide leads to reduced helper virus‐free HSV‐1 amplicon expression titers via suppression of ICP0

  2008cites this paper
• Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

  2006cites this paper
• Seemingly Diverse Activities of I 3-Alethine '

  2006cites this paper
• Role of Transforming Growth Factor ßtin Induction of Colon Carcinoma Differentiation by Hexamethylene Bisacetamide1

  2006cites this paper
• A Phase I unavailability and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered via Nasogastric Tube1

  2006influential citation
• Approaches to optimal dosing of hexamethylene bisacetamide

  2004influential citation
• New synergistic combinations of differentiation inducing agents in the treatment of acute myeloid leukaemia

  2004cites this paper
• Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells

  2004cites this paper
• HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells

  2004cites this paper
• The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide

  2004cites this paper
• Membrane Phospholipid Reorganization Differentially Regulates Metallothionein and Heme Oxygenase by Heme–Hemopexin

  2002cites this paper
• Histone deacetylase: a target for antiproliferative and antiprotozoal agents.

  2001cites this paper
• The chelate effect in binding, catalysis, and chemotherapy

  2000cites this paper
• Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

  1999cites this paper
• DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION?

  1998cites this paper
• Growth and Maturation Factors in Cancer

  1998cites this paper
• Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants.

  1998cites this paper
• Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide.

  1998cites this paper
• Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells.

  1996cites this paper
• Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents.

  1996cites this paper
• Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis.

  1996cites this paper
• Induced differentiation, the cell cycle, and the treatment of cancer.

  1996cites this paper
• Glial differentiation: a review with implications for new directions in neuro-oncology.

  1995cites this paper
• NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line.

  1994cites this paper
• Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.

  1994cites this paper
• Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells

  1994cites this paper
• Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography.

  1994cites this paper
• Seemingly diverse activities of beta-alethine.

  1994cites this paper
• Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation

  1993cites this paper
• Novel polyamide inducers of HL-60 cellular differentiation

  1993cites this paper
• Differentiation: a suitable strategy for cancer chemotherapy?

  1993cites this paper
• NEW DIRECTIONS FOR THE ANTI‐RETROVIRAL CHEMOTHERAPY OF AIDS ‐ A BASIS FOR A PHARMACOLOGICAL APPROACH TO TREATMENT

  1993cites this paper
• Induction of phenotypic changes in SCLC cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP.

  1993cites this paper
• Individualizing dosing of cancer chemotherapy.

  1993cites this paper
• Use of Platelets and Other Transfusion Products in Patients with Malignancy

  1992cites this paper
• Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts

  1992cites this paper
• Action of exogenous differentiating agents on gene expression in cancer cells.

  1992cites this paper
• Use of blood components in cancer patients with bleeding.

  1992cites this paper
• Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.

  1992cites this paper
• Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

  1992cites this paper
• Potent cytodifferentiating agents related to hexamethylenebisacetamide.

  1991cites this paper
• Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells.

  1991cites this paper
• Phase II trial of N-methylformamide in patients with metastatic melanoma

  1991cites this paper
• Presence of histamine H2-receptors on human gastric carcinoma cell line MKN-45 and their increase by retinoic acid treatment.

  1991cites this paper
• Enhanced replication of herpes simplex virus by hexamethylene bisacetamide.

  1991cites this paper
• Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.

  1991cites this paper
• Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.

  1990cites this paper
• Effect of hexamethylene bisacetamide and cyclosporin A on recovery of herpes simplex virus type 2 from the in vitro model of latency in a human neuroblastoma cell line.

  1990cites this paper
• Enhancement of the radiosensitivity of two human tumour cell lines by hexamethylene bisacetamide.

  1990cites this paper
• Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.

  1990cites this paper
• Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide.

  1990cites this paper
• Potentiation of natural killer cell activity and tumor immunity by diacetylputrescine.

  1990cites this paper
• Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60.

  1990cites this paper
• Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide.

  1990cites this paper
• Induced Differentiation of Transformed Cells by Polar Compounds: From Molecular Studies to Clinical Trials

  1989cites this paper
• Lymphoid neoplasia and the control of haemopoietic differentiation.

  1989cites this paper
• Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential.

  1989cites this paper
• Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamide.

  1989cites this paper
• Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.

  1988cites this paper